

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

FURTHER ANNOUNCEMENT

UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 30 September 2025 (the “**Announcement**”) in relation to a discloseable transaction involving the Proposed H Share Listing of CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”). Unless otherwise defined therein, capitalised terms in this announcement shall have the same meanings as those defined in the Announcement.

The Board announces that on 10 December 2025, CSPC Innovation submitted a listing application to the Stock Exchange to apply for the Proposed H Share Listing. It is expected that CSPC Innovation will remain as an indirect subsidiary of the Company upon completion of the Proposed H Share Listing. Details of the Proposed H Share Listing, including the expected timetable, the size and structure of the offering (if any) under the Proposed H Share Listing, have not yet been finalised.

The completion of the Proposed H Share Listing is still conditional upon, among other things, the completion of filing procedures with and/or approvals from relevant governmental authorities and regulatory authorities, such as the CSRC, the Stock Exchange and the SFC. The Company will provide further update on the progress of the Proposed H Share Listing as and when appropriate.

A redacted version of the application proof of CSPC Innovation’s listing document submitted to the Stock Exchange (the “**Application Proof**”) is available for download on the Stock Exchange’s website at <https://www1.hkexnews.hk/app/appindex.html>. The Application Proof contains, among other things, certain business and financial information relating to CSPC Innovation Group. Shareholders and potential investors of the Company should note that the Application Proof is in draft form, and the information contained in it is incomplete and is subject to change which may be material.

Shareholders and potential investors of the Company should note that, the Proposed H Share Listing is subject to, among other things, the prevailing market conditions and completion of filing procedures with and/or approvals from relevant authorities (including the CSRC, the Stock Exchange and the SFC). Accordingly, Shareholders and potential investors of the Company should be aware that, the Company does not guarantee that the Proposed H Share Listing will materialise, nor the timing thereof. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. The Company will make further announcement(s) to disclose material development in respect of the Proposed H Share Listing as and when appropriate.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 11 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.